Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5817 in obesity
NCT06934408Phase 1Recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in obesity comparing HRS-5817 Injection Group with Placebo Group (2 arms). Primary endpoint: Adverse Events at 253 days. Started May 2025; status: recruiting.
02
Drugs
HRS-5817
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06934408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934408.